𝔖 Bobbio Scriptorium
✦   LIBER   ✦

749 CLINICAL IMPLICATION OF HEPATITIS B VIRAL LOAD IN HEPATITIS B E ANTIGEN-NEGATIVE CHRONIC HEPATITIS B PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH CURATIVE RESECTION

✍ Scribed by J.H. Shim; H.C. Lee; J.G. Choi; D. Lee; K.M. Kim; Y.-S. Lim; Y.-H. Chung; Y.S. Lee; D.J. Suh

Book ID
117379893
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
90 KB
Volume
54
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characterization of viral kinetics in pa
Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B
✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60